Skip to Main Content
American Flag
LABOR DAY SALE

50% off your first year of any Quiver subscription

...

Use Promo Code:

LABOR26
American Flag

Biogen Inc. Common Stock

BIIB Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Forecast
Insiders
Institutions
Compensation
Government
Ownership
News
Income
Balance Sheet
Cash Flow
Revenue Breakdown

Recent trades of BIIB by members of U.S. Congress

Politician Type Traded
Kevin Hern House / R Sale $1,001 - $15,000 Aug 18, 2026
Gilbert Ray Cisneros, Jr. House / D Purchase $1,001 - $15,000 Jun 05, 2026
Maria Elvira Salazar House / R Sale $15,001 - $50,000 Jun 02, 2026
Ro Khanna House / D Sale $1,001 - $15,000 May 27, 2026
Ro Khanna House / D Purchase $1,001 - $15,000 May 15, 2026
Maria Elvira Salazar House / R Purchase $1,001 - $15,000 May 12, 2026
Maria Elvira Salazar House / R Purchase $1,001 - $15,000 May 11, 2026
Maria Elvira Salazar House / R Purchase $50,001 - $100,000 May 11, 2026
Ro Khanna House / D Sale $1,001 - $15,000 Apr 13, 2026
Alan Armstrong Senate / R Purchase $1,001 - $15,000 Mar 27, 2026
Ro Khanna House / D Sale $1,001 - $15,000 Feb 06, 2026
Gilbert Ray Cisneros, Jr. House / D Purchase $1,001 - $15,000 Jan 30, 2026
Ro Khanna House / D Purchase $1,001 - $15,000 Jan 29, 2026
Ro Khanna House / D Purchase $1,001 - $15,000 Aug 26, 2025
Ro Khanna House / D Purchase $1,001 - $15,000 Aug 26, 2025
Ro Khanna House / D Sale $1,001 - $15,000 May 19, 2025
Robert Bresnahan House / R Purchase $1,001 - $15,000 May 15, 2025
Ro Khanna House / D Purchase $1,001 - $15,000 Apr 23, 2025
Robert Bresnahan House / R Sale $1,001 - $15,000 Apr 08, 2025
Robert Bresnahan House / R Purchase $1,001 - $15,000 Feb 25, 2025
Ro Khanna House / D Purchase $1,001 - $15,000 Feb 25, 2025
Ro Khanna House / D Sale $1,001 - $15,000 Feb 19, 2025
Ro Khanna House / D Sale $1,001 - $15,000 Jan 17, 2025
Ro Khanna House / D Purchase $1,001 - $15,000 Nov 15, 2024
Byron Donalds House / R Sale $1,001 - $15,000 N/A
Ro Khanna House / D Purchase $1,001 - $15,000 Oct 14, 2024
Ro Khanna House / D Purchase $1,001 - $15,000 N/A
Ro Khanna House / D Sale $1,001 - $15,000 Aug 05, 2024
Ro Khanna House / D Purchase $1,001 - $15,000 Aug 02, 2024
Ro Khanna House / D Purchase $1,001 - $15,000 Aug 02, 2024
Ro Khanna House / D Purchase $1,001 - $15,000 N/A
Ro Khanna House / D Purchase $1,001 - $15,000 Apr 26, 2024
Ro Khanna House / D Sale $1,001 - $15,000 Mar 25, 2024
Ro Khanna House / D Sale $1,001 - $15,000 Mar 20, 2024
Ro Khanna House / D Exchange None Mar 05, 2024
Ro Khanna House / D Purchase $1,001 - $15,000 Jan 10, 2024
Ro Khanna House / D Purchase $1,001 - $15,000 Dec 05, 2023
Ro Khanna House / D Sale $1,001 - $15,000 Dec 04, 2023
Ro Khanna House / D Sale $1,001 - $15,000 Nov 03, 2023
Ro Khanna House / D Purchase $1,001 - $15,000 Oct 10, 2023
Ro Khanna House / D Purchase $1,001 - $15,000 Oct 02, 2023
Ro Khanna House / D Sale $1,001 - $15,000 Sep 06, 2023
Ro Khanna House / D Sale $1,001 - $15,000 Aug 29, 2023
Ro Khanna House / D Sale $1,001 - $15,000 Apr 10, 2023
Daniel S. Goldman House / D Sale $1,001 - $15,000 Mar 06, 2023
Ro Khanna House / D Purchase $1,001 - $15,000 Feb 10, 2023
Ro Khanna House / D Sale $1,001 - $15,000 N/A
Shri Thanedar House / D Sale $15,001 - $50,000 Jan 23, 2023
Ro Khanna House / D Purchase $1,001 - $15,000 Nov 03, 2022
Ro Khanna House / D Purchase $1,001 - $15,000 Aug 25, 2022
BIIB Stock Insider Trading Activity Follow @QuiverQuant for major insider updates

---

Closing Price
Purchase
Sale
Name
Type
Shares
Price
Shares Held
Date
Reported
BIIB Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
BIIB Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported

Recently reported changes in BIIB holdings by institutional investors

Quarterly net insider trading by BIIB's directors and management

* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.

About

Backtest Start Date
CAGR (Total)
Return (30d)
Return (1Y)
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • MAX

About

Backtest Start Date

Key Metrics

Return (1d)

Return (30d)

Return (1Y)

CAGR (Total)

Max Drawdown

Beta

Alpha

Sharpe Ratio

Win Rate

Average Win

Average Loss

Annual Volatility

Annual Std Dev

Information Ratio

Treynor Ratio

Total Trades

Show More
Metrics Definitions

Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.

  • Alpha

    Measures a portfolio's risk-adjusted performance against that of its benchmark

    Learn More about Alpha
  • Annual Standard Deviation

    Measures how much the portfolio's total return varies from its mean or average.

    Learn More about Annual Standard Deviation
  • Annual Volatility

    A statistical measure of the dispersion of returns for the portfolio.

    Learn More about Annual Volatility
  • Average Win

    The average return (%) for trades that resulted in a positive return.

  • Average Loss

    The average return (%) for trades that resulted in a negative return.

  • Beta

    A measure of the volatility of the portfolio compared to the market as a whole.

    Learn More about Beta
  • CAGR

    CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.

    Learn More about CAGR
  • Information Ratio

    A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.

    Learn More about Information Ratio
  • Max Drawdown

    the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.

    Learn More about Max Drawdown
  • Sharpe Ratio

    The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.

    Learn More about Sharpe Ratio
  • Total Trades

    The total number of trades made by this strategy.

  • Treynor Ratio

    Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.

    Learn More about Treynor Ratio
  • Win Rate

    The percentage of total trades that resulted in a positive return.

Subscribe to Quiver Premium for insider trading alerts

Be the first to see our newest insights and key updates across all datasets.

schema-2

Government lobbying spending instances

  • $1,060,000 Jul 20, 2026 Issue: Health Issues Medicare/Medicaid Pharmacy Taxation/Internal Revenue Code Trade (domestic/foreign)
  • $1,460,000 Apr 20, 2026 Issue: Medicare/Medicaid Health Issues Pharmacy Taxation/Internal Revenue Code Trade (domestic/foreign)
  • $770,000 Jan 19, 2026 Issue: Medicare/Medicaid Pharmacy Taxation/Internal Revenue Code Trade (domestic/foreign) Health Issues
  • $990,000 Oct 20, 2025 Issue: Pharmacy Taxation/Internal Revenue Code Health Issues Medicare/Medicaid Trade (domestic/foreign)
  • $1,380,000 Jul 20, 2025 Issue: Health Issues Medicare/Medicaid Pharmacy Taxation/Internal Revenue Code Manufacturing Trade (domestic/foreign)
  • $1,020,000 Apr 21, 2025 Issue: Medicare/Medicaid Pharmacy Manufacturing Trade (domestic/foreign) Taxation/Internal Revenue Code Copyright/Patent/Trademark Health Issues
  • $700,000 Jan 20, 2025 Issue: Health Issues Medicare/Medicaid Pharmacy Taxation/Internal Revenue Code Copyright/Patent/Trademark Manufacturing
  • $710,000 Oct 19, 2024 Issue: Copyright/Patent/Trademark Trade (domestic/foreign) Taxation/Internal Revenue Code Pharmacy Medicare/Medicaid Health Issues
  • $1,670,000 Jul 22, 2024 Issue: Copyright/Patent/Trademark Trade (domestic/foreign) Taxation/Internal Revenue Code Pharmacy Medicare/Medicaid Health Issues
  • $830,000 Feb 13, 2024 Issue: Copyright/Patent/Trademark Budget/Appropriations Trade (domestic/foreign) Taxation/Internal Revenue Code Pharmacy Medicare/Medicaid Health Issues
  • $940,000 Jan 21, 2024 Issue: Transportation Copyright/Patent/Trademark Trade (domestic/foreign) Taxation/Internal Revenue Code Pharmacy Medicare/Medicaid Health Issues
  • $1,090,000 Oct 19, 2023 Issue: Copyright/Patent/Trademark Trade (domestic/foreign) Taxation/Internal Revenue Code Pharmacy Medicare/Medicaid Health Issues
  • $900,000 Jan 20, 2023 Issue: Budget/Appropriations Trade (domestic/foreign) Taxation/Internal Revenue Code Pharmacy Medicare/Medicaid Health Issues
  • $940,000 Nov 08, 2022 Issue: Copyright/Patent/Trademark Taxation/Internal Revenue Code Pharmacy Medicare/Medicaid Health Issues
  • $900,000 Oct 20, 2022 Issue: Trade (domestic/foreign) Copyright/Patent/Trademark Taxation/Internal Revenue Code Pharmacy Medicare/Medicaid Health Issues
  • $1,060,000 Apr 19, 2022 Issue: Taxation/Internal Revenue Code Pharmacy Medicare/Medicaid Health Issues
  • $670,000 Jan 20, 2022 Issue: None
  • $910,000 Oct 19, 2021 Issue: None
  • $980,000 Jul 19, 2021 Issue: None
  • $1,570,000 Apr 20, 2021 Issue: None
  • $890,000 Jan 21, 2021 Issue: None
  • $1,150,000 Oct 19, 2020 Issue: None
  • $760,000 Jul 20, 2020 Issue: None
  • $1,090,000 Apr 20, 2020 Issue: None
  • $266,680 Jan 22, 2020 Issue: None
  • $560,000 Oct 21, 2019 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign)
  • $280,000 Jul 22, 2019 Issue: Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign) Medicare/Medicaid
  • $810,000 Apr 22, 2019 Issue: Copyright/Patent/Trademark Taxation/Internal Revenue Code Health Issues Medicare/Medicaid Trade (domestic/foreign)
  • $790,000 Jan 22, 2019 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign)
  • $810,000 Oct 22, 2018 Issue: Taxation/Internal Revenue Code Trade (domestic/foreign) Health Issues Medicare/Medicaid Copyright/Patent/Trademark
  • $890,000 Jul 18, 2018 Issue: Medicare/Medicaid Taxation/Internal Revenue Code Trade (domestic/foreign) Copyright/Patent/Trademark Health Issues
  • $730,000 Apr 19, 2018 Issue: Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign) Medicare/Medicaid Health Issues
  • $590,000 Jan 18, 2018 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign)
  • $640,000 Oct 17, 2017 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Trade (domestic/foreign) Taxation/Internal Revenue Code
  • $710,000 Jul 17, 2017 Issue: Health Issues Copyright/Patent/Trademark Trade (domestic/foreign) Taxation/Internal Revenue Code Medicare/Medicaid
  • $740,000 Apr 18, 2017 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign)
  • $630,000 Jan 18, 2017 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign)
  • $710,000 Oct 19, 2016 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign)
  • $730,000 Jul 19, 2016 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign)
  • $620,000 Apr 20, 2016 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign)
  • $540,000 Jan 19, 2016 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign)
  • $570,000 Oct 19, 2015 Issue: Health Issues Copyright/Patent/Trademark Trade (domestic/foreign) Medicare/Medicaid Taxation/Internal Revenue Code
  • $580,000 Jul 20, 2015 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign)
  • $540,000 Apr 20, 2015 Issue: Health Issues Copyright/Patent/Trademark Trade (domestic/foreign) Taxation/Internal Revenue Code Medicare/Medicaid
  • $430,000 Jan 16, 2015 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code Trade (domestic/foreign) Copyright/Patent/Trademark
  • $460,000 Oct 19, 2014 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Trade (domestic/foreign) Taxation/Internal Revenue Code
  • $405,000 Jul 21, 2014 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code Trade (domestic/foreign) Copyright/Patent/Trademark
  • $405,000 Apr 18, 2014 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign)
  • $395,000 Jan 16, 2014 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code Trade (domestic/foreign) Copyright/Patent/Trademark
  • $395,000 Oct 17, 2013 Issue: Health Issues Taxation/Internal Revenue Code Trade (domestic/foreign) Medicare/Medicaid
  • $435,000 Jul 22, 2013 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code Trade (domestic/foreign)
  • $400,000 Apr 22, 2013 Issue: Health Issues Trade (domestic/foreign) Medicare/Medicaid Taxation/Internal Revenue Code
  • $360,000 Jan 22, 2013 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code Trade (domestic/foreign) Copyright/Patent/Trademark
  • $415,000 Oct 19, 2012 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code Trade (domestic/foreign)
  • $440,000 Jul 18, 2012 Issue: Health Issues Taxation/Internal Revenue Code Medicare/Medicaid Trade (domestic/foreign)
  • $445,000 Apr 19, 2012 Issue: Health Issues Medicare/Medicaid Trade (domestic/foreign) Taxation/Internal Revenue Code
  • $520,000 Jan 18, 2012 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code Trade (domestic/foreign)
  • $480,000 Oct 20, 2011 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Trade (domestic/foreign) Taxation/Internal Revenue Code
  • $390,000 Jul 20, 2011 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign)
  • $420,000 Apr 18, 2011 Issue: Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Medicare/Medicaid
  • $335,000 Jan 20, 2011 Issue: Medicare/Medicaid Copyright/Patent/Trademark Health Issues Taxation/Internal Revenue Code
  • $365,000 Oct 19, 2010 Issue: Health Issues Copyright/Patent/Trademark Medicare/Medicaid Taxation/Internal Revenue Code
  • $240,000 Jul 20, 2010 Issue: Copyright/Patent/Trademark Health Issues Taxation/Internal Revenue Code Medicare/Medicaid
  • $290,000 Apr 19, 2010 Issue: Health Issues Taxation/Internal Revenue Code Copyright/Patent/Trademark Medicare/Medicaid
  • $290,000 Jan 19, 2010 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code
  • $350,000 Oct 19, 2009 Issue: Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Medicare/Medicaid
  • $300,000 Jul 28, 2009 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code
  • $290,000 Apr 20, 2009 Issue: Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Medicare/Medicaid
  • $170,000 Jan 16, 2009 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark
  • $180,000 Oct 16, 2008 Issue: Medicare/Medicaid Copyright/Patent/Trademark Health Issues
  • $180,000 Oct 16, 2008 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark
  • $200,000 Apr 18, 2008 Issue: Health Issues Copyright/Patent/Trademark Medicare/Medicaid
  • $620,000 Feb 13, 2008 Issue: Copyright/Patent/Trademark Health Issues Medicare/Medicaid
  • $620,000 Aug 13, 2007 Issue: Health Issues Copyright/Patent/Trademark
  • $281,000 Feb 14, 2007 Issue: Health Issues Medicare/Medicaid
  • $286,000 Aug 11, 2006 Issue: Medicare/Medicaid Pharmacy Health Issues
  • $380,000 Feb 14, 2006 Issue: Medicare/Medicaid
  • $510,000 Oct 27, 2005 Issue: Medical/Disease Research/Clinical Labs Medicare/Medicaid Budget/Appropriations
  • $430,000 Sep 06, 2005 Issue: Medicare/Medicaid Budget/Appropriations Taxation/Internal Revenue Code Health Issues
  • $370,000 Jun 21, 2004 Issue: Medicare/Medicaid Health Issues
  • $420,000 Jun 21, 2004 Issue: None
  • $60,000 Oct 22, 2003 Issue: Medicare/Medicaid
  • $50,000 Aug 25, 2003 Issue: Medicare/Medicaid
  • $60,000 Aug 13, 2003 Issue: Health Issues Medicare/Medicaid
  • $80,000 Aug 04, 2003 Issue: Retirement Health Issues Medicare/Medicaid
  • $60,000 Aug 01, 2003 Issue: None
  • $66,490 Jul 17, 2003 Issue: Health Issues
  • $30,000 Jun 11, 2003 Issue: None
  • $44,569 Mar 14, 2003 Issue: Health Issues
  • $20,000 Feb 25, 2003 Issue: Budget/Appropriations
  • $60,000 Feb 24, 2003 Issue: Medicare/Medicaid
  • $60,000 Feb 14, 2003 Issue: Health Issues Medicare/Medicaid
  • $100,000 Feb 14, 2003 Issue: Retirement Health Issues Medicare/Medicaid
  • $20,000 Feb 06, 2003 Issue: Copyright/Patent/Trademark Health Issues Medicare/Medicaid
  • $40,000 Feb 04, 2003 Issue: Budget/Appropriations
  • $60,000 Aug 19, 2002 Issue: Budget/Appropriations
  • $100,000 Aug 19, 2002 Issue: Medicare/Medicaid Insurance
  • $60,000 Aug 14, 2002 Issue: Health Issues
  • $60,000 Aug 14, 2002 Issue: Medicare/Medicaid
  • $60,000 Aug 13, 2002 Issue: Copyright/Patent/Trademark Medicare/Medicaid Health Issues

Former government officials who have lobbied for BIIB

62 former government officials from 38 congressional offices at 12 lobbying firms have lobbied for BIIB, most recently Jul 21, 2026.

  • Paul Brathwaite Congress New Executive Director, Congressional Black Caucus; Deputy Assistant Secretary of Labor, ESA, Department of Labor; Chief of Staff, ESA, Department of Labor; and Special Assistant, U.S. Secretary of Labor, Department of Labor. Formerly Executive Director, Congressional Black Caucus; Deputy Assistant Secretary of La · FEDERAL STREET STRATEGIES, LLC · Jul 21, 2026
  • Andy Levin
    Ven Neralla House New Chief of Staff, U.S. Rep. Andy Levin; Deputy Chief of Staff,U.S. Rep. Pramila Jayapal; Legislative Director, U.S. Rep.Barbara Lee; Legislative Assistant, U.S. Rep. Peter DeFazio;Senior Advisor, USDA; OPP; and MCC. Formerly with Andy Levin · FEDERAL STREET STRATEGIES, LLC · Jul 21, 2026
  • Amy Klobuchar
    Kaade Wallace Senate New Legislative Correspondent, U.S. Senator Amy Klobuchar; Staff Assistant, U.S. Representative Betty McCollum Formerly with Amy Klobuchar · FEDERAL STREET STRATEGIES, LLC · Jul 21, 2026
  • Zoe Lofgren
    Stacey Leavandosky House New Chief of Staff, U.S. Representative Zoe Lofgren; Senior Advisor, Committee on Science, Space & Technology; Senior Advisor, Committee on House Administration; Executive Director, California Democratic Congressional Delegation. Formerly with Zoe Lofgren · FEDERAL STREET STRATEGIES, LLC · Jul 21, 2026
  • John B. Shadegg
    Paul Edattel House Chief Health Counsel, House Energy & Commerce Committee; Policy Assistant, Office of the Speaker; Professional Staff Member for the Majority at the House Energy & Commerce Committee; Legislative Assistant & Legislative Director, Rep. John Shadegg Formerly with John B. Shadegg · TODD STRATEGY GROUP · Jul 20, 2026
  • Daniel Todd Senate Senior Health Counsel, Senate Finance Committee; Special Assistant, Office of Admin. Ct. - Medicare & Medicaid Formerly Senior Health Counsel, Senate Finance Committee; Special Assistant, Office of Ad · TODD STRATEGY GROUP · Jul 20, 2026
  • Brett Guthrie
    Eric Bergren House Chief of Staff, Rep. Brett Guthrie; Staff Assistant, Legislative Correspondent, Legislative Assistant, Senior Legislative Assistant, Legislative Director, Chief of Staff - Rep. Ron Lewis; Intern, Rep. Bill Baker Formerly with Brett Guthrie · TODD STRATEGY GROUP · Jul 20, 2026
  • Brett Guthrie
    Katherine Cotton House Staff Assistant, Legislative Correspondent, Legislative Assistant - U.S. Representative Brett Guthrie Formerly with Brett Guthrie · TODD STRATEGY GROUP · Jul 20, 2026
See all 62 on the Revolving Door dashboard

BIIB Estimated quarterly lobbying spending

BIIB Revenue by Segment or Geography

By Segment
By Geography
BIIB Income Statement
BIIB Balance Sheet
BIIB Cash Flow
U.S. Patents

New BIIB patent grants

  • Patent Title: Cytoprotective agent Jan. 03, 2023
  • Patent Title: Hydrophobic interaction protein chromatography under no-salt conditions Jun. 12, 2018
  • Patent Title: Control of protein glycosylation by culture medium supplementation and cell culture process parameters Apr. 17, 2018
  • Patent Title: Compounds that are s1p modulating agents and/or atx modulating agents Apr. 17, 2018
  • Patent Title: Pyrimidinyl tyrosine kinase inhibitors Apr. 17, 2018
  • Patent Title: Compositions and methods for modulation of smn2 splicing in a subject Mar. 27, 2018
  • Patent Title: Anti-blood dendritic cell antigen 2 antibodies and uses thereof Feb. 27, 2018
  • Patent Title: Method for the treatment of inflammatory disorders Feb. 27, 2018
  • Patent Title: S1p and/or atx modulating agents Dec. 26, 2017
  • Patent Title: Bicyclic aryl sphingosine 1-phosphate analogs Nov. 28, 2017
  • Patent Title: Biaryl inhibitors of bruton's tyrosine kinase Nov. 07, 2017
  • Patent Title: S1p modulating agents Nov. 07, 2017
  • Patent Title: Lingo-2 antagonists for treatment of conditions involving motor neurons Oct. 24, 2017
  • Patent Title: Methods of preventing and removing trisulfide bonds Oct. 17, 2017
  • Patent Title: Treating neurological disorders Oct. 03, 2017
  • Patent Title: S1p and/or atx modulating agents Sep. 26, 2017
  • Patent Title: S1p modulating agents Sep. 19, 2017
  • Patent Title: Display screen with graphical user interface Sep. 12, 2017
  • Patent Title: Display screen with a graphical user interface Aug. 29, 2017
  • Patent Title: Anti-α Aug. 29, 2017
  • Patent Title: Compositions comprising antibodies to lingo or fragments thereof Aug. 29, 2017
  • Patent Title: Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto Aug. 22, 2017
  • Patent Title: Method of treating lupus nephritis Aug. 15, 2017
  • Patent Title: Anti-vla-4 related assays Aug. 08, 2017
  • Patent Title: Compositions and methods for modulation of smn2 splicing in a subject Aug. 01, 2017
  • Patent Title: Methods and products for evaluating an immune response to a therapeutic protein Jul. 18, 2017
  • Patent Title: Heterobicyclic sphingosine 1-phosphate analogs Jul. 18, 2017
  • Patent Title: Methods for the detection of jc polyoma virus Jul. 04, 2017
  • Patent Title: Enhancement of transport of therapeutic molecules across the blood brain barrier Jun. 13, 2017
  • Patent Title: Methods of treating autoimmune diseases using a b-cell maturation antigen (bcma) May. 16, 2017
  • Patent Title: Antibodies to vla-1 May. 09, 2017
  • Patent Title: Macrocyclic compounds as irak4 inhibitors for the treatment of inflammatory diseases Apr. 11, 2017
  • Patent Title: Human anti-tau antibodies Mar. 21, 2017
  • Patent Title: Display screen with graphical user interface Mar. 14, 2017
  • Patent Title: Display screen with graphical user interface Mar. 14, 2017
  • Patent Title: Trapping reagents for reactive metabolites screening Feb. 28, 2017
  • Patent Title: Bicyclic aryl sphingosine 1-phosphate analogs Feb. 21, 2017
  • Patent Title: Jcv neutralizing antibodies Feb. 14, 2017
  • Patent Title: Jcv neutralizing antibodies Feb. 14, 2017
  • Patent Title: Methods of preventing and removing trisulfide bonds Feb. 07, 2017
  • Patent Title: Atx modulating agents Jan. 31, 2017
  • Patent Title: Compounds that are s1p modulating agents and/or atx modulating agents Jan. 24, 2017
  • Patent Title: Baff, inhibitors thereof and their use in the modulation of b-cell response and treatment of autoimmune disorders Jan. 17, 2017
  • Patent Title: Methods of treating inflammatory disorders using high concentration natalizumab compositions Jan. 03, 2017
  • Patent Title: Atx modulating agents Dec. 20, 2016
  • Patent Title: Stable liquid interferon beta formulations Dec. 20, 2016
  • Patent Title: Display screen with graphical user interface Dec. 06, 2016
  • Patent Title: Spectroscopic analysis of nutrient materials for use in a cell culture process Nov. 29, 2016
  • Patent Title: Syringe Mar. 15, 2016
  • Patent Title: Package Oct. 27, 2015
Government Contracts

Estimated quarterly amount awarded to BIIB from public contracts

BIIB News

Recent insights relating to BIIB

CNBC Recommendations

Recent picks made for BIIB stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in BIIB

BIIB Analyst Ratings

BIIB Stock Forecasts
...

  • ... Highest Price Target
  • ... Median Price Target
  • ... Lowest Price Target
BIIB Analyst Forecasts
Analyst
Firm
Current
Previous
Date
Frequently Asked Questions
  • Is $BIIB stock a Buy, Sell, or Hold?

  • What is the price target for $BIIB stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

BIIB Top Shareholders
Shareholder
Shares Held
BIIB Options Owners
Shareholder
Security
Underlying Shares
Frequently Asked Questions
  • Who owns $BIIB stock?

  • Who owns the most shares of $BIIB stock?

  • What funds own $BIIB stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

BIIB Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view BIIB Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
About BIIB

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

  • Address Cambridge, MA
  • Market Cap 33.6 billion
  • Employees 7,500
  • Industrial Classification Biological Products, (No Diagnostic Substances)

Biogen Inc. Common Stock (BIIB) Historical Stock Prices

Biogen Inc. Common Stock (BIIB) closed at $227.53 on September 23, 2026. Over the past year its adjusted close ranged from $135.67 to $227.53. Daily prices go back to January 2, 2014, 3,198 trading days in all.

  • 1 month+4.31%
  • 3 months+14.00%
  • Year to date+29.29%
  • 1 year+63.33%
  • 3 years-11.70%
  • 5 years-22.00%
  • Max-11.94%
See every congressional and insider trade on the BIIB price chart

Quiver Premium charts BIIB's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.

Upgrade to Premium

Last 12 months, newest first

Access Raw Data Daily prices since 2014 for every ticker, through the Quiver API
DateOpenHighLowCloseAdj. CloseVolume
Sep 23, 2026 226.94 229.19 222.35 227.53 227.53 1,494,492
Sep 22, 2026 219.22 226.43 219.00 225.36 225.36 1,112,343
Sep 21, 2026 216.14 221.92 214.59 219.07 219.07 928,562
Sep 18, 2026 219.05 220.17 215.26 215.50 215.50 2,636,086
Sep 17, 2026 217.68 219.41 215.33 219.05 219.05 836,707
Sep 16, 2026 216.41 218.29 214.81 216.01 216.01 606,493
Sep 15, 2026 216.71 216.71 213.54 216.17 216.17 756,047
Sep 14, 2026 221.00 222.25 215.56 217.36 217.36 629,931
Sep 11, 2026 216.75 219.76 214.71 217.15 217.15 1,075,556
Sep 10, 2026 209.92 216.70 208.93 215.43 215.43 936,643
Sep 9, 2026 210.50 213.48 209.00 210.73 210.73 694,669
Sep 8, 2026 215.45 217.28 210.54 212.50 212.50 617,829
Sep 4, 2026 221.15 223.82 219.82 220.83 220.83 465,108
Sep 3, 2026 225.44 225.80 221.23 224.51 224.51 550,745
Sep 2, 2026 218.20 225.59 216.97 222.67 222.67 1,268,282
Sep 1, 2026 218.11 219.30 213.60 216.04 216.04 785,496
Aug 31, 2026 216.47 218.89 213.58 216.65 216.65 831,004
Aug 28, 2026 221.17 222.00 216.78 218.50 218.50 517,484
Aug 27, 2026 219.39 222.11 217.53 221.50 221.50 497,524
Aug 26, 2026 219.34 222.00 218.69 221.07 221.07 647,334
Aug 25, 2026 218.93 222.85 218.00 220.77 220.77 495,435
Aug 24, 2026 216.40 218.50 213.96 218.12 218.12 649,828
Aug 21, 2026 217.76 219.12 215.00 216.78 216.78 722,347
Aug 20, 2026 217.98 221.29 214.16 214.35 214.35 808,625
Aug 19, 2026 215.33 222.15 215.07 221.56 221.56 886,914
Aug 18, 2026 211.00 214.06 210.01 212.55 212.55 694,009
Aug 17, 2026 208.36 210.49 207.62 209.15 209.15 617,238
Aug 14, 2026 210.01 210.79 208.22 209.83 209.83 554,816
Aug 13, 2026 212.98 215.60 208.79 210.65 210.65 860,094
Aug 12, 2026 203.52 209.22 201.00 208.87 208.87 789,441
Aug 11, 2026 206.63 207.57 203.53 203.89 203.89 936,834
Aug 10, 2026 206.70 210.02 206.29 207.13 207.13 706,425
Aug 7, 2026 207.38 208.31 204.16 207.94 207.94 840,566
Aug 6, 2026 208.75 209.03 202.03 206.28 206.28 892,772
Aug 5, 2026 210.60 212.18 205.80 206.63 206.63 873,781
Aug 4, 2026 200.96 209.74 199.93 208.45 208.45 1,205,704
Aug 3, 2026 203.34 203.85 199.58 201.82 201.82 940,993
Jul 31, 2026 207.51 208.05 202.57 202.95 202.95 1,062,258
Jul 30, 2026 204.38 210.19 203.09 207.93 207.93 892,938
Jul 29, 2026 210.50 218.59 206.26 209.23 209.23 2,400,174
Jul 28, 2026 201.01 207.72 199.40 205.61 205.61 1,832,179
Jul 27, 2026 202.75 204.47 199.83 200.14 200.14 762,581
Jul 24, 2026 202.24 203.30 200.03 202.19 202.19 596,372
Jul 23, 2026 197.04 203.60 196.91 200.62 200.62 1,032,070
Jul 22, 2026 203.70 204.31 197.40 197.74 197.74 841,350
Jul 21, 2026 199.47 203.70 198.59 203.16 203.16 652,841
Jul 20, 2026 204.08 205.65 199.62 199.95 199.95 963,088
Jul 17, 2026 208.60 215.79 203.40 205.99 205.99 1,151,283
Jul 16, 2026 198.26 209.64 194.67 208.92 208.92 1,872,778
Jul 15, 2026 191.21 198.58 186.03 197.24 197.24 2,067,350
Jul 14, 2026 200.34 202.00 189.40 191.95 191.95 3,902,309
Jul 13, 2026 199.33 210.87 197.74 209.03 209.03 2,259,821
Jul 10, 2026 197.63 199.98 194.37 199.15 199.15 1,133,120
Jul 9, 2026 198.92 201.01 196.00 198.91 198.91 1,657,327
Jul 8, 2026 204.86 206.75 198.93 200.36 200.36 1,947,888
Jul 7, 2026 211.86 212.00 205.65 205.70 205.70 1,156,880
Jul 6, 2026 215.95 215.95 208.27 208.46 208.46 1,218,492
Jul 2, 2026 212.74 219.01 210.75 216.12 216.12 1,155,165
Jul 1, 2026 215.25 215.81 209.67 209.74 209.74 1,138,639
Jun 30, 2026 218.00 218.00 212.58 216.06 216.06 1,091,325
Jun 29, 2026 215.74 219.72 214.08 216.63 216.63 1,279,990
Jun 26, 2026 202.53 218.06 202.29 216.03 216.03 2,374,525
Jun 25, 2026 201.63 206.67 200.20 201.96 201.96 1,328,911
Jun 24, 2026 199.34 202.06 198.66 199.59 199.59 1,349,120
Jun 23, 2026 198.88 201.22 197.01 197.19 197.19 1,053,492
Jun 22, 2026 199.48 200.97 194.74 199.71 199.71 1,675,111
Jun 18, 2026 200.22 200.99 193.19 196.58 196.58 1,729,826
Jun 17, 2026 195.14 201.75 194.03 198.67 198.67 1,009,032
Jun 16, 2026 199.69 200.26 194.04 195.61 195.61 1,110,656
Jun 15, 2026 198.37 199.37 195.89 198.64 198.64 883,963
Jun 12, 2026 200.57 203.45 199.06 200.05 200.05 837,294
Jun 11, 2026 195.49 201.18 194.24 199.96 199.96 914,781
Jun 10, 2026 200.21 201.94 194.10 194.24 194.24 1,071,228
Jun 9, 2026 195.51 199.63 193.45 199.10 199.10 934,191
Jun 8, 2026 197.25 198.69 192.18 192.62 192.62 1,162,350
Jun 5, 2026 196.45 200.66 195.14 195.34 195.34 880,438
Jun 4, 2026 198.00 199.90 196.34 196.45 196.45 719,127
Jun 3, 2026 187.69 196.50 187.48 195.96 195.96 891,787
Jun 2, 2026 190.09 190.58 184.90 188.83 188.83 1,098,098
Jun 1, 2026 194.50 195.28 191.67 192.23 192.23 841,499
May 29, 2026 195.55 198.46 195.11 196.00 196.00 1,905,488
May 28, 2026 196.97 198.00 194.50 196.39 196.39 556,331
May 27, 2026 194.11 199.80 194.11 196.97 196.97 893,048
May 26, 2026 194.30 195.50 192.27 193.08 193.08 930,212
May 22, 2026 190.53 194.75 190.00 193.76 193.76 892,933
May 21, 2026 187.40 190.27 185.85 189.47 189.47 1,475,348
May 20, 2026 191.41 193.38 186.37 187.80 187.80 919,894
May 19, 2026 191.72 193.03 188.64 190.56 190.56 1,054,138
May 18, 2026 191.25 193.37 189.19 191.91 191.91 1,051,356
May 15, 2026 191.83 194.91 190.66 192.95 192.95 1,252,270
May 14, 2026 200.25 205.00 189.49 191.37 191.37 2,812,933
May 13, 2026 199.33 205.97 198.86 204.53 204.53 1,272,026
May 12, 2026 198.47 202.40 196.47 199.36 199.36 1,145,749
May 11, 2026 194.76 200.31 194.75 197.95 197.95 1,772,229
May 8, 2026 189.68 195.20 189.50 193.45 193.45 931,578
May 7, 2026 190.34 192.10 188.86 191.38 191.38 735,692
May 6, 2026 189.13 191.16 188.30 190.68 190.68 741,346
May 5, 2026 187.38 189.69 186.00 189.13 189.13 586,074
May 4, 2026 186.28 187.51 185.44 187.21 187.21 626,559
May 1, 2026 189.28 190.57 186.14 187.06 187.06 696,812
Apr 30, 2026 194.02 195.98 187.16 189.28 189.28 1,550,523
Apr 29, 2026 183.12 195.89 180.18 194.38 194.38 2,453,836
Apr 28, 2026 182.45 184.41 181.89 183.38 183.38 1,235,813
Apr 27, 2026 183.16 186.15 179.15 180.67 180.67 1,101,370
Apr 24, 2026 186.65 186.65 183.17 184.38 184.38 723,366
Apr 23, 2026 189.46 190.32 187.01 187.88 187.88 816,281
Apr 22, 2026 189.31 192.75 188.67 190.07 190.07 1,328,297
Apr 21, 2026 184.52 187.74 181.75 185.95 185.95 1,063,303
Apr 20, 2026 179.54 184.26 178.72 183.34 183.34 1,484,371
Apr 17, 2026 176.29 178.41 175.69 177.35 177.35 1,239,458
Apr 16, 2026 178.81 179.99 174.85 176.02 176.02 953,722
Apr 15, 2026 179.36 180.87 177.70 180.54 180.54 1,168,801
Apr 14, 2026 177.71 181.77 177.45 178.96 178.96 1,550,580
Apr 13, 2026 172.62 176.79 171.22 176.37 176.37 1,414,958
Apr 10, 2026 177.97 177.97 172.32 172.97 172.97 1,501,979
Apr 9, 2026 177.81 180.06 174.97 177.11 177.11 1,266,491
Apr 8, 2026 178.24 180.24 176.35 179.90 179.90 1,289,686
Apr 7, 2026 172.20 175.64 170.43 175.61 175.61 1,515,806
Apr 6, 2026 177.00 177.39 168.64 172.34 172.34 2,149,104
Apr 2, 2026 181.46 182.23 176.39 177.34 177.34 1,339,297
Apr 1, 2026 183.16 186.31 181.71 183.78 183.78 1,390,216
Mar 31, 2026 179.46 184.68 171.37 183.33 183.33 2,719,977
Mar 30, 2026 186.16 190.09 185.50 187.57 187.57 799,935
Mar 27, 2026 191.06 191.06 183.01 183.84 183.84 935,104
Mar 26, 2026 189.00 192.28 188.35 191.06 191.06 879,198
Mar 25, 2026 184.91 189.38 184.91 189.18 189.18 775,195
Mar 24, 2026 182.63 184.84 180.33 183.94 183.94 644,275
Mar 23, 2026 183.48 185.00 183.00 183.64 183.64 1,011,752
Mar 20, 2026 183.13 183.69 180.47 181.46 181.46 2,214,268
Mar 19, 2026 182.18 185.44 181.68 183.41 183.41 768,649
Mar 18, 2026 184.13 184.31 180.48 182.31 182.31 846,255
Mar 17, 2026 184.73 186.52 183.20 185.29 185.29 810,219
Mar 16, 2026 182.75 184.62 181.88 183.26 183.26 995,911
Mar 13, 2026 185.99 188.00 181.46 181.55 181.55 1,092,301
Mar 12, 2026 187.86 188.91 184.63 184.90 184.90 851,563
Mar 11, 2026 187.54 192.99 187.54 190.48 190.48 864,392
Mar 10, 2026 187.69 190.78 187.02 188.41 188.41 687,662
Mar 9, 2026 183.91 188.50 182.60 188.24 188.24 651,626
Mar 6, 2026 186.25 186.25 181.24 184.87 184.87 772,906
Mar 5, 2026 187.97 190.99 185.95 188.08 188.08 893,331
Mar 4, 2026 185.06 190.37 183.16 189.94 189.94 952,927
Mar 3, 2026 185.01 187.05 181.79 184.02 184.02 1,049,925
Mar 2, 2026 190.22 190.75 186.72 188.05 188.05 691,597
Feb 27, 2026 187.51 192.46 186.62 191.82 191.82 1,402,201
Feb 26, 2026 190.30 190.74 185.90 188.02 188.02 988,117
Feb 25, 2026 194.22 196.73 189.89 190.73 190.73 942,723
Feb 24, 2026 196.03 198.72 194.43 195.13 195.13 716,382
Feb 23, 2026 191.82 197.05 189.11 196.34 196.34 878,939
Feb 20, 2026 190.78 192.59 189.95 192.03 192.03 799,225
Feb 19, 2026 193.51 195.00 191.05 192.08 192.08 993,273
Feb 18, 2026 195.32 195.68 193.11 194.13 194.13 1,049,036
Feb 17, 2026 197.46 200.29 193.37 195.62 195.62 986,535
Feb 13, 2026 196.27 199.50 195.52 196.52 196.52 1,352,792
Feb 12, 2026 190.15 196.00 189.00 195.50 195.50 1,657,480
Feb 11, 2026 188.35 192.00 187.20 191.20 191.20 996,929
Feb 10, 2026 194.07 195.72 188.74 188.99 188.99 1,836,221
Feb 9, 2026 199.83 201.00 191.88 193.81 193.81 2,096,252
Feb 6, 2026 187.01 202.41 184.60 201.18 201.18 3,404,876
Feb 5, 2026 184.87 187.73 184.54 185.36 185.36 2,542,641
Feb 4, 2026 177.25 186.24 177.10 185.45 185.45 2,076,363
Feb 3, 2026 177.79 182.67 176.19 176.76 176.76 1,594,142
Feb 2, 2026 179.30 180.76 177.58 179.09 179.09 1,288,816
Jan 30, 2026 177.09 180.14 175.96 179.89 179.89 1,487,978
Jan 29, 2026 174.88 177.20 173.51 176.18 176.18 1,146,709
Jan 28, 2026 173.63 175.06 170.85 174.83 174.83 1,304,662
Jan 27, 2026 173.02 176.14 172.23 174.12 174.12 748,078
Jan 26, 2026 171.67 174.31 170.59 173.12 173.12 1,049,188
Jan 23, 2026 173.17 173.90 170.04 171.59 171.59 1,250,463
Jan 22, 2026 171.78 175.29 171.65 173.80 173.80 996,425
Jan 21, 2026 165.31 172.87 165.31 172.62 172.62 1,447,089
Jan 20, 2026 161.51 165.61 160.36 165.38 165.38 1,879,947
Jan 16, 2026 168.87 169.34 163.74 164.42 164.42 1,816,538
Jan 15, 2026 169.03 169.79 166.79 168.57 168.57 1,562,727
Jan 14, 2026 177.73 178.41 165.58 169.31 169.31 3,635,883
Jan 13, 2026 185.42 186.32 177.05 178.30 178.30 1,597,380
Jan 12, 2026 188.00 188.00 182.73 185.63 185.63 1,280,360
Jan 9, 2026 186.74 190.20 186.49 187.62 187.62 1,416,702
Jan 8, 2026 187.02 187.77 183.50 186.00 186.00 1,622,749
Jan 7, 2026 181.70 187.06 181.70 186.91 186.91 2,122,447
Jan 6, 2026 174.94 182.97 174.30 182.61 182.61 2,115,650
Jan 5, 2026 175.73 180.56 171.61 174.63 174.63 1,663,631
Jan 2, 2026 175.37 178.24 174.28 177.82 177.82 1,095,744
Dec 31, 2025 175.76 177.19 175.02 175.99 175.99 890,441
Dec 30, 2025 176.30 176.99 175.72 176.40 176.40 609,867
Dec 29, 2025 177.00 178.46 176.31 176.83 176.83 928,193
Dec 26, 2025 175.30 177.19 175.00 177.08 177.08 687,403
Dec 24, 2025 175.73 177.18 175.37 176.33 176.33 434,748
Dec 23, 2025 174.26 175.58 173.08 174.82 174.82 1,281,705
Dec 22, 2025 174.78 177.29 172.90 174.70 174.70 1,909,529
Dec 19, 2025 171.32 176.42 170.00 174.80 174.80 14,994,759
Dec 18, 2025 171.59 173.00 168.56 169.91 169.91 2,761,018
Dec 17, 2025 171.43 173.83 169.55 172.10 172.10 2,783,560
Dec 16, 2025 174.51 174.51 169.52 171.50 171.50 2,408,490
Dec 15, 2025 173.67 175.94 170.45 175.74 175.74 2,291,589
Dec 12, 2025 173.49 175.08 171.27 174.10 174.10 1,781,471
Dec 11, 2025 177.47 180.79 172.00 172.50 172.50 2,721,790
Dec 10, 2025 173.30 178.17 169.24 177.55 177.55 2,147,901
Dec 9, 2025 179.91 181.99 175.39 175.84 175.84 1,506,685
Dec 8, 2025 181.30 182.12 179.21 180.44 180.44 1,474,568
Dec 5, 2025 181.96 183.15 181.10 181.30 181.30 1,209,961
Dec 4, 2025 181.86 182.69 179.27 181.98 181.98 1,246,342
Dec 3, 2025 180.17 182.94 178.05 180.75 180.75 1,845,129
Dec 2, 2025 177.32 180.54 174.53 180.18 180.18 1,866,647
Dec 1, 2025 180.15 181.78 175.88 177.78 177.78 1,947,020
Nov 28, 2025 182.07 182.74 180.69 182.09 182.09 566,362
Nov 26, 2025 181.96 183.93 180.76 181.94 181.94 1,483,073
Nov 25, 2025 177.07 182.97 176.09 181.96 181.96 2,344,782
Nov 24, 2025 177.65 185.17 175.57 176.82 176.82 4,164,240
Nov 21, 2025 168.54 176.02 167.42 175.30 175.30 2,268,169
Nov 20, 2025 168.15 170.91 165.75 168.18 168.18 1,914,503
Nov 19, 2025 168.83 168.90 165.79 167.93 167.93 1,765,993
Nov 18, 2025 164.40 170.78 163.00 168.83 168.83 2,257,470
Nov 17, 2025 167.00 167.97 163.50 164.68 164.68 2,245,006
Nov 14, 2025 164.72 169.00 163.00 167.55 167.55 2,620,813
Nov 13, 2025 161.57 167.87 161.20 164.73 164.73 2,993,001
Nov 12, 2025 160.00 162.56 158.05 161.48 161.48 1,659,866
Nov 11, 2025 156.76 159.95 154.20 159.56 159.56 1,504,613
Nov 10, 2025 155.41 156.55 153.77 156.26 156.26 1,258,595
Nov 7, 2025 156.70 156.70 151.83 155.51 155.51 1,552,011
Nov 6, 2025 155.76 157.80 153.76 156.74 156.74 1,848,716
Nov 5, 2025 149.66 153.68 148.51 153.43 153.43 1,806,070
Nov 4, 2025 150.89 152.90 149.05 149.33 149.33 2,029,011
Nov 3, 2025 153.60 155.33 149.63 151.44 151.44 2,197,357
Oct 31, 2025 147.99 155.18 146.52 154.27 154.27 2,235,290
Oct 30, 2025 140.10 154.44 138.00 149.61 149.61 2,745,188
Oct 29, 2025 148.82 149.91 147.54 147.86 147.86 2,450,701
Oct 28, 2025 150.01 150.30 148.37 149.13 149.13 1,662,855
Oct 27, 2025 150.07 150.92 148.10 150.43 150.43 1,214,395
Oct 24, 2025 151.09 151.92 148.98 149.89 149.89 1,338,315
Oct 23, 2025 148.99 150.29 147.57 150.08 150.08 1,245,964
Oct 22, 2025 147.37 149.12 146.25 147.72 147.72 1,403,299
Oct 21, 2025 146.09 147.89 144.29 146.22 146.22 895,048
Oct 20, 2025 143.31 147.47 142.41 146.63 146.63 1,316,452
Oct 17, 2025 142.10 144.32 141.67 143.00 143.00 1,010,007
Oct 16, 2025 144.05 147.48 141.70 142.26 142.26 1,469,099
Oct 15, 2025 144.74 145.19 142.29 143.66 143.66 1,337,176
Oct 14, 2025 144.09 146.88 142.19 145.31 145.31 1,283,553
Oct 13, 2025 146.47 147.56 144.65 144.69 144.69 1,124,466
Oct 10, 2025 150.00 150.20 144.74 146.57 146.57 1,724,990
Oct 9, 2025 151.37 152.15 148.17 149.61 149.61 1,600,465
Oct 8, 2025 152.36 152.36 149.64 150.97 150.97 1,333,277
Oct 7, 2025 154.52 154.57 151.97 152.21 152.21 1,372,833
Oct 6, 2025 159.60 159.70 153.10 154.05 154.05 1,817,888
Oct 3, 2025 156.46 160.20 155.97 159.88 159.88 2,878,796
Oct 2, 2025 154.00 157.85 152.22 155.25 155.25 2,882,551
Oct 1, 2025 140.82 154.44 140.70 154.22 154.22 4,059,913
Sep 30, 2025 138.46 141.04 136.94 140.08 140.08 1,369,066
Sep 29, 2025 137.49 138.80 135.39 138.52 138.52 1,285,534
Sep 26, 2025 136.79 138.00 135.81 137.37 137.37 1,677,223
Sep 25, 2025 138.40 140.67 135.41 135.67 135.67 1,260,311
Sep 24, 2025 138.52 139.28 136.20 137.67 137.67 1,309,389
Sep 23, 2025 140.27 141.38 138.72 139.31 139.31 1,103,063

Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.

Need daily prices for every ticker, in code?

The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.

Explore the Quiver API
Biogen Inc. Common Stock Executive Compensation

We estimate that -- received a compensation of -- in --, making them the highest paid executive at BIIB, per a recent SEC DEF 14A filing. We estimate that the median employee at BIOGEN INC. is paid $183,062.



Name
Role
Salary
Bonus
Stock/Option Awards
Total Compensation